Neuronetics Inc (STIM)
NASDAQ:STIM
Want to see STIM full AI Analyst Report?
STIM Stock Chart & Stats
$1.42
-$0.02(-1.30%)
At close: 4:00 PM EST
$1.42
-$0.02(-1.30%)
Day’s Range― - ―
52-Week Range$0.80 - $4.85
Previous CloseN/A
Volume92.55K
Average Volume (3M)2.13M
Market Cap
$89.07M
Enterprise Value$99.95M
Total Cash (Recent Filing)$13.21M
Total Debt (Recent Filing)$24.09M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding69,587,840
10 Day Avg. Volume2,260,318
30 Day Avg. Volume2,125,807
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue0.66
Enterprise Value/Gross Profit1.37
Enterprise Value/Ebitda-3.82
Forecast
1Y Price Target
$3.00Price Target Upside111.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$161.10M
Bulls Say, Bears Say
Bulls Say
LeadershipAnalyst views the appointment of Dan Reuvers as CEO as a strong leadership move given his experience and the firm's improving revenues that bring it closer to profitability.
Operational PerformanceThe combined company achieving positive cash flow from operations supports the view that scale strengthens the business and reduces operating cash burn.
PartnershipsA collaboration with Compass Pathways to offer COMP360 leverages vertical integration and expands the company’s depression treatment platform, enhancing commercial reach.
Bears Say
Corporate Structure UncertaintyAn independent shareholder calling for a review of strategic alternatives, including a potential sale of the TMS business, creates uncertainty about the company's structure and long-term strategy.
Guidance GapManagement providing no forward guidance leaves the company's future revenue trajectory unclear and may increase investor uncertainty about growth visibility.
Valuation PressureAnalyst lowering the price target and repositioning the firm into a micro-cap med‑tech peer group signals a more conservative valuation backdrop that could weigh on the stock.
Neuronetics News
STIM FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was $0.80 and its highest was $4.85 in the past 12 months.
What is Neuronetics Inc’s market cap?
Neuronetics Inc’s market cap is $89.07M.
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 86 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on May 05, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.174 by $0.014.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -0.12.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 69,587,840 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.174. Following the earnings report the stock price went up 7.426%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (111.27% Upside)
$3.00 (111.27% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 533.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 12.2%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.23%
12-Months-Change
Fundamentals
Return on Equity
-164.68%
Trailing 12-Months
Asset Growth
-11.65%
Trailing 12-Months
Company Description
Neuronetics Inc
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a mixed but constructive view: top-line growth (total revenue +8%, clinic revenue +15%), improved profitability trends (narrower net loss and $2.0M adjusted EBITDA improvement), and meaningful operational initiatives (cost savings, go-to-market pilots, payer/regulatory tailwinds). Offsetting these positives are ongoing challenges including NeuroStar treatment revenue declines, gross margin contraction, a materially reduced cash balance ($19.0M vs $34.1M at year-end), continued GAAP losses and a near-term projected operating cash burn for the year. Management emphasized discipline, cash-flow focus, and pilots to expand reach — signaling a path to stabilization but with execution and liquidity risks to manage in the near term.View all STIM earnings summariesSTIM Stock 12 Month Forecast
Average Price Target
$3.00
▲(111.27% Upside)
Technical Analysis
Ownership Overview
51.32% Insiders
5.63% Mutual Funds
4.82% Other Institutional Investors
31.97% Public Companies and
Individual Investors